Annovis Bio, Inc.
ANVS
$1.57
-$0.07-4.27%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.92% | 65.57% | 32.05% | -40.70% | -3.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.50% | -70.48% | -20.46% | -21.66% | 33.87% |
| Operating Income | 35.50% | 70.48% | 20.46% | 21.66% | -33.87% |
| Income Before Tax | 73.60% | 14.12% | 47.36% | 89.04% | -187.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.60% | 14.12% | 47.36% | 89.04% | -187.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.60% | 14.12% | 47.36% | 89.04% | -187.51% |
| EBIT | 35.50% | 70.48% | 20.46% | 21.66% | -33.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 81.01% | 40.36% | 58.33% | 91.55% | -136.49% |
| Normalized Basic EPS | 81.01% | 40.36% | 58.33% | 91.54% | -136.48% |
| EPS Diluted | 78.65% | 40.36% | 58.50% | -20.79% | -136.49% |
| Normalized Diluted EPS | 81.01% | 40.36% | 58.33% | 91.70% | -136.48% |
| Average Basic Shares Outstanding | 38.99% | 43.98% | 26.33% | 29.65% | 21.57% |
| Average Diluted Shares Outstanding | 38.99% | 43.98% | 26.33% | 32.09% | 21.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |